9:00am Chair Introduction

Bruce Levine, Professor, Cancer Gene Therapy, University of Pennsylvania

09:05am Presentation: Unleashing the Allogeneic Potential by Using Large Scale Automated Manufacturing Platforms

• Thinking from the end backwards to streamline the process and create agility from R&D to commercial scale
• Combining closed and automated systems with in-process controls to increase reproducibility and batch to batch consistency

Lior Raviv, Chief Technical Officer, Pluri

09:20am Presentation: Designing Flexible Capabilities and Capacity in a Complex Cell Therapy Market

• Cell Therapy market definition and segmentation
• Main cell therapy types, processes and equipment
• Facility layout definition and practical examples
• Designing QC space for cell therapy

 Luca Alberici, General Manager, AGC Biologics Milan

09:35am Presentation: CellPryme – Novel Enhancements for Cell Therapies

• CellPryme-M is a method for cell manufacturing that improves in vivo persistence
• CellPryme-A is an adjuvant approach that addresses the immunosuppressive TME
• We have shown the synergy between the two technologies

Rebecca Lim, Senior Vice President, Scientific Affairs, Prescient Therapeutics

09:50am Presentation: Benefits of Real-Time Analytics to Overcome Common Cell Culture Challenges

• Advanced analytics are required to monitor and control critical process parameters in today’s diverse and intensified processes used in cell and gene therapies
• We will discuss a data-driven and accelerated process optimization approach leveraging sensitive, online (sample-free) monitoring of Glucose& Lactate with automated feed control and at-line amino acid analysis

Wolfgang Künnecke, Vice President of Bioanalytics, 908Devices

10:05am Panel Discussion and  Q&A

With all session participants